These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
450 related articles for article (PubMed ID: 11051546)
1. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Fata JE; Kong YY; Li J; Sasaki T; Irie-Sasaki J; Moorehead RA; Elliott R; Scully S; Voura EB; Lacey DL; Boyle WJ; Khokha R; Penninger JM Cell; 2000 Sep; 103(1):41-50. PubMed ID: 11051546 [TBL] [Abstract][Full Text] [Related]
2. IKKalpha provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development. Cao Y; Bonizzi G; Seagroves TN; Greten FR; Johnson R; Schmidt EV; Karin M Cell; 2001 Dec; 107(6):763-75. PubMed ID: 11747812 [TBL] [Abstract][Full Text] [Related]
3. Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation. Huang L; Xu J; Wood DJ; Zheng MH Am J Pathol; 2000 Mar; 156(3):761-7. PubMed ID: 10702390 [TBL] [Abstract][Full Text] [Related]
4. A novel in vivo role for osteoprotegerin ligand in activation of monocyte effector function and inflammatory response. Seshasayee D; Wang H; Lee WP; Gribling P; Ross J; Van Bruggen N; Carano R; Grewal IS J Biol Chem; 2004 Jul; 279(29):30202-9. PubMed ID: 15145935 [TBL] [Abstract][Full Text] [Related]
6. Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Lacey DL; Tan HL; Lu J; Kaufman S; Van G; Qiu W; Rattan A; Scully S; Fletcher F; Juan T; Kelley M; Burgess TL; Boyle WJ; Polverino AJ Am J Pathol; 2000 Aug; 157(2):435-48. PubMed ID: 10934148 [TBL] [Abstract][Full Text] [Related]
7. Activin A stimulates IkappaB-alpha/NFkappaB and RANK expression for osteoclast differentiation, but not AKT survival pathway in osteoclast precursors. Sugatani T; Alvarez UM; Hruska KA J Cell Biochem; 2003 Sep; 90(1):59-67. PubMed ID: 12938156 [TBL] [Abstract][Full Text] [Related]
8. Molecular control of bone remodeling and osteoporosis. Kong YY; Penninger JM Exp Gerontol; 2000 Oct; 35(8):947-56. PubMed ID: 11121682 [TBL] [Abstract][Full Text] [Related]
9. Osteoprotegerin and osteoprotegerin ligand effects on osteoclast formation from human peripheral blood mononuclear cell precursors. Shalhoub V; Faust J; Boyle WJ; Dunstan CR; Kelley M; Kaufman S; Scully S; Van G; Lacey DL J Cell Biochem; 1999 Feb; 72(2):251-61. PubMed ID: 10022507 [TBL] [Abstract][Full Text] [Related]
10. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. Burgess TL; Qian Y; Kaufman S; Ring BD; Van G; Capparelli C; Kelley M; Hsu H; Boyle WJ; Dunstan CR; Hu S; Lacey DL J Cell Biol; 1999 May; 145(3):527-38. PubMed ID: 10225954 [TBL] [Abstract][Full Text] [Related]
11. Osteoprotegerin ligand induces beta-casein gene expression through the transcription factor CCAAT/enhancer-binding protein beta. Kim HJ; Yoon MJ; Lee J; Penninger JM; Kong YY J Biol Chem; 2002 Feb; 277(7):5339-44. PubMed ID: 11726661 [TBL] [Abstract][Full Text] [Related]
12. [The effects of 17 beta-estradiol on the expression of osteoprotegerin, the ligand of osteoprotegerin and related cytokines in osteosarcoma MG63 cells]. Su X; Liao EY; Peng J; Wu XP Zhonghua Nei Ke Za Zhi; 2003 Nov; 42(11):800-3. PubMed ID: 14636471 [TBL] [Abstract][Full Text] [Related]
13. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Hsu H; Lacey DL; Dunstan CR; Solovyev I; Colombero A; Timms E; Tan HL; Elliott G; Kelley MJ; Sarosi I; Wang L; Xia XZ; Elliott R; Chiu L; Black T; Scully S; Capparelli C; Morony S; Shimamoto G; Bass MB; Boyle WJ Proc Natl Acad Sci U S A; 1999 Mar; 96(7):3540-5. PubMed ID: 10097072 [TBL] [Abstract][Full Text] [Related]
14. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Kong YY; Feige U; Sarosi I; Bolon B; Tafuri A; Morony S; Capparelli C; Li J; Elliott R; McCabe S; Wong T; Campagnuolo G; Moran E; Bogoch ER; Van G; Nguyen LT; Ohashi PS; Lacey DL; Fish E; Boyle WJ; Penninger JM Nature; 1999 Nov; 402(6759):304-9. PubMed ID: 10580503 [TBL] [Abstract][Full Text] [Related]
15. Characterization of osteoclast precursors in human blood. Shalhoub V; Elliott G; Chiu L; Manoukian R; Kelley M; Hawkins N; Davy E; Shimamoto G; Beck J; Kaufman SA; Van G; Scully S; Qi M; Grisanti M; Dunstan C; Boyle WJ; Lacey DL Br J Haematol; 2000 Nov; 111(2):501-12. PubMed ID: 11122091 [TBL] [Abstract][Full Text] [Related]
16. Receptor activator of NF-kappaB ligand induction via Jak2 and Stat5a in mammary epithelial cells. Srivastava S; Matsuda M; Hou Z; Bailey JP; Kitazawa R; Herbst MP; Horseman ND J Biol Chem; 2003 Nov; 278(46):46171-8. PubMed ID: 12952963 [TBL] [Abstract][Full Text] [Related]
17. Osteoprotegerin ligand and osteoprotegerin: novel implications for osteoclast biology and bone metabolism. Hofbauer LC Eur J Endocrinol; 1999 Sep; 141(3):195-210. PubMed ID: 10474114 [No Abstract] [Full Text] [Related]
18. Receptor activator of NF-kappaB ligand regulates the proliferation of mammary epithelial cells via Id2. Kim NS; Kim HJ; Koo BK; Kwon MC; Kim YW; Cho Y; Yokota Y; Penninger JM; Kong YY Mol Cell Biol; 2006 Feb; 26(3):1002-13. PubMed ID: 16428453 [TBL] [Abstract][Full Text] [Related]